Dec 16, 2024, 17:31
GemCis-NabPaclitaxel vs. GemCis in first line of advanced biliary tract cancers
Erman Akkus shared on X:
“GemCis-NabPaclitaxel vs. GemCis in 1L of advanced biliary tract cancers
SWOG S1815
No PFS or OS benefit
PFS benefit in gallbladder cancer subgroup.”
Authors: Rachna T. Shroff, Gentry King, Sarah Colby, Aaron J. Scott, Mitesh J. Borad, Laura Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Imane El Dika, Benjamin Tan, Puneet Cheema, Anuj Patel, Renuka Iyer, R. Katie Kelley, Jaykumar Thumar, Anthony El-Khoueiry, Katherine A. Guthrie, E. Gabriela Chiorean, Howard Hochster, and Philip A. Philip.
Aaron J. Scott
Amit Mahipal
Anthony El-Khoueiry
Anuj Patel
Aparna Kalyan
Benjamin Tan
cancer
E. Gabriela Chiorean
Erman Akkus
Gentry King
Howard Hochster
Imane El Dika
Jaykumar Thumar
Katherine A. Guthrie
Khalid Matin
Laura Goff
Milind M. Javle
Mitesh J. Borad
OncoDaily
Oncology
Philip A. Philip
Puneet Cheema
R. Katie Kelley
Rachna T. Shroff
Renuka Iyer
Sarah Colby
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 16, 2024, 17:26
Dec 16, 2024, 17:22
Dec 16, 2024, 17:20
Dec 16, 2024, 17:18
Dec 16, 2024, 17:12
Dec 16, 2024, 17:05
Dec 16, 2024, 16:52
Dec 16, 2024, 16:48
Dec 16, 2024, 16:39